North Star Asset Management Inc. continued to hold its stake in Stryker Corp. (NYSE:SYK) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 92,455 shares of the medical technology company’s stock at the end of the second quarter. Stryker Corp. accounts for 1.2% of North Star Asset Management Inc.’s investment portfolio, making the stock its 25th largest position. North Star Asset Management Inc.’s holdings in Stryker Corp. were worth $9,919,000 as of its most recent SEC filing.
Several other large investors have also recently bought and sold shares of the stock. Carroll Financial Associates Inc. raised its stake in Stryker Corp. by 78.0% in the second quarter. Carroll Financial Associates Inc. now owns 1,086 shares of the medical technology company’s stock valued at $130,000 after buying an additional 476 shares in the last quarter. CWM LLC purchased a new stake in Stryker Corp. during the second quarter valued at about $150,000. Lau Associates LLC purchased a new stake in Stryker Corp. during the second quarter valued at about $204,000. Brightworth purchased a new stake in Stryker Corp. during the second quarter valued at about $211,000. Finally, Leavell Investment Management Inc. purchased a new stake in Stryker Corp. during the second quarter valued at about $250,000. 75.49% of the stock is currently owned by institutional investors and hedge funds.
Shares of Stryker Corp. (NYSE:SYK) traded down 0.29% during midday trading on Friday, reaching $116.31. The company had a trading volume of 914,709 shares. The company’s 50-day moving average is $115.00 and its 200-day moving average is $113.75. The firm has a market cap of $43.54 billion, a P/E ratio of 27.42 and a beta of 0.72. Stryker Corp. has a 52-week low of $86.68 and a 52-week high of $123.55.
Stryker Corp. (NYSE:SYK) last released its earnings results on Thursday, July 21st. The medical technology company reported $1.39 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.37 by $0.02. The company earned $2.84 billion during the quarter, compared to analysts’ expectations of $2.79 billion. Stryker Corp. had a return on equity of 23.61% and a net margin of 15.33%. Equities research analysts expect that Stryker Corp. will post $5.76 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Monday, October 31st. Stockholders of record on Friday, September 30th will be paid a $0.38 dividend. The ex-dividend date of this dividend is Wednesday, September 28th. This represents a $1.52 annualized dividend and a dividend yield of 1.30%. Stryker Corp.’s dividend payout ratio (DPR) is currently 35.85%.
Several research firms recently issued reports on SYK. Canaccord Genuity reissued a “buy” rating and set a $130.00 price target on shares of Stryker Corp. in a research report on Sunday, July 24th. JPMorgan Chase & Co. restated a “hold” rating and set a $119.00 price objective on shares of Stryker Corp. in a research note on Friday, July 22nd. Piper Jaffray Cos. upped their price objective on Stryker Corp. from $120.00 to $135.00 and gave the stock an “overweight” rating in a research note on Friday, July 22nd. Credit Suisse Group AG restated an “outperform” rating and set a $124.00 price objective (up from $110.00) on shares of Stryker Corp. in a research note on Tuesday, July 19th. Finally, Jefferies Group restated a “hold” rating and set a $120.00 price objective (up from $113.00) on shares of Stryker Corp. in a research note on Monday, July 25th. Four analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $114.91.
In other news, Director Ronda E. Stryker sold 6,000 shares of Stryker Corp. stock in a transaction on Tuesday, July 12th. The stock was sold at an average price of $122.75, for a total value of $736,500.00. Following the completion of the sale, the director now directly owns 193,142 shares of the company’s stock, valued at approximately $23,708,180.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Ronda E. Stryker sold 12,000 shares of Stryker Corp. stock in a transaction on Wednesday, October 5th. The shares were sold at an average price of $116.34, for a total value of $1,396,080.00. Following the completion of the sale, the director now directly owns 193,142 shares of the company’s stock, valued at $22,470,140.28. The disclosure for this sale can be found here. 7.80% of the stock is owned by insiders.
Stryker Corp. Company Profile
Stryker Corporation (Stryker) is a medical technology company. The Company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Company’s Orthopaedics segment products consist of implants used in hip and knee joint replacements and trauma and surgeries. The Company’s MedSurg segment products consist of surgical equipment and surgical navigation systems (Instruments); endoscopic and communications systems (Endoscopy); patient handling and emergency medical equipment (Medical), and reprocessed and remanufactured medical devices (Sustainability), as well as other medical device products used in a range of medical specialties.
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corp. (NYSE:SYK).
Receive News & Ratings for Stryker Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corp. and related companies with MarketBeat.com's FREE daily email newsletter.